Bora Biologics: Commercialization as the New Competitive Filter
PHARMAnetwork Magazine, April 2026.
Commercialization is Becoming the Industry’s New Competitive Filter
As regulatory expectations evolve and biologics pipelines expand, the real differentiator is no longer early-stage agility — it’s execution discipline at commercial scale.
We’re proud to share that PHARMAnetwork has featured our latest article:
“Commercialization as the New Competitive Filter: How Regulatory Evolution and Pipeline Expansion Are Redefining Biologics Manufacturing”
Authored by
Steve Lam, Chief Executive Officer
Marc Goemans, MSc MBA, Chief Commercial Officer
In the piece, we explore:
• Why late-stage readiness is redefining CDMO selection
• How regulatory rigor is shaping commercial manufacturing models
• The growing importance of execution certainty at scale
• Why geography and supply alignment now influence commercialization strategy
As more biologics programs approach Phase III and licensure, sponsors are asking a different question:
Not “Who has capacity?”
But “Who can execute reliably under commercial conditions?”
View on PHARMAnetwork Magazine
Now Operational: 2000L Single-Use Commercial Capacity in the U.S.
Bora Biologics’ expanded 2000L single-use capabilities support late-stage development and commercial GMP manufacturing in our San Diego FDA registered facility.
